Bohus M, Stoffers-Winterling J, Sharp C, Krause-Utz A, Schmahl C, Lieb K. Borderline personality disorder. Lancet. 2021;398:1528–40. https://doi.org/10.1016/S0140-6736(21)00476-1.

Article  PubMed  Google Scholar 

Zanarini MC, Horwood J, Wolke D, Waylen A, Fitzmaurice G, Grant BF. Prevalence of DSM-IV borderline personality disorder in two community samples: 6,330 English 11-year-olds and 34,653 American adults. J Pers Disord. 2011;25:607–19. https://doi.org/10.1521/pedi.2011.25.5.607.

Article  PubMed  PubMed Central  Google Scholar 

Trull TJ, Jahng S, Tomko RL, Wood PK, Sher KJ. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24:412–26. https://doi.org/10.1521/pedi.2010.24.4.412.

Article  PubMed  PubMed Central  Google Scholar 

Schmahl C, Herpertz SC, Bertsch K, Ende G, Flor H, Kirsch P, et al. Mechanisms of disturbed emotion processing and social interaction in borderline personality disorder: state of knowledge and research agenda of the German Clinical Research Unit. Borderline Personal Disord Emot Dysregul. 2014;1:12. https://doi.org/10.1186/2051-6673-1-12.

Article  PubMed  PubMed Central  Google Scholar 

Herpertz SC, Bertsch K, Jeung H. Neurobiology of criterion a: self and interpersonal personality functioning. Curr Opin Psychol. 2018;21:23–7. https://doi.org/10.1016/j.copsyc.2017.08.032.

Article  PubMed  Google Scholar 

Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev. 2010;117:623–36. https://doi.org/10.1037/a0018095.

Article  PubMed  Google Scholar 

Anderson G. Pathoetiology and pathophysiology of borderline personality: Role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. Prog Neuropsychopharmacol Biol Psychiatry. 2020;98:109782. https://doi.org/10.1016/j.pnpbp.2019.109782.

Article  CAS  PubMed  Google Scholar 

Panksepp J, Nelson E, Siviy S. Brain opioids and mother-infant social motivation. Acta Paediatr Suppl. 1994;397:40–6. https://doi.org/10.1111/j.1651-2227.1994.tb13264.x.

Article  CAS  PubMed  Google Scholar 

Narayanan S, Lam H, Christian L, Levine MS, Grandy D, Rubinstein M, et al. Endogenous opioids mediate basal hedonic tone independent of dopamine D-1 or D-2 receptor activation. Neuroscience. 2004;124:241–6. https://doi.org/10.1016/j.neuroscience.2003.11.011.

Article  CAS  PubMed  Google Scholar 

Turtonen O, Saarinen A, Nummenmaa L, Tuominen L, Tikka M, Armio RL, et al. Adult attachment system links with brain mu-opioid receptor availability in vivo. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:360–9. https://doi.org/10.1016/j.bpsc.2020.10.013.

Article  PubMed  Google Scholar 

Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36:195–206. https://doi.org/10.1016/j.tins.2012.11.002.

Article  CAS  PubMed  Google Scholar 

Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314:44–55. https://doi.org/10.1016/j.brainres.2009.08.062.

Article  CAS  PubMed  Google Scholar 

Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci. 2012;69:857–96. https://doi.org/10.1007/s00018-011-0844-x.

Article  CAS  PubMed  Google Scholar 

Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008;28:407–14. https://doi.org/10.1523/JNEUROSCI.4458-07.2008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prossin AR, Love TM, Koeppe RA, Zubieta JK, Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry. 2010;167:925–33. https://doi.org/10.1176/appi.ajp.2010.09091348.

Article  PubMed  PubMed Central  Google Scholar 

Timäus C, Meiser M, Wiltfang J, Bandelow B, Wedekind D. Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. Hum Psychopharmacol. 2021;36:e2800. https://doi.org/10.1002/hup.2800.

Article  CAS  PubMed  Google Scholar 

Martin-Blanco A, Patrizi B, Soler J, Gasol X, Elices M, Gasol M, et al. Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol. 2017;32:231–4. https://doi.org/10.1097/YIC.0000000000000170.

Article  PubMed  Google Scholar 

Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491–8. https://doi.org/10.1176/appi.ajp.2015.15040535.

Article  PubMed  Google Scholar 

Enning F, Schmahl C. Behandlung dissoziativer Symptome mit Nalmefen bei Patienten mit Borderline-Persönlichkeitsstörung und komplexer posttraumatischer Belastungsstörung [Treatment of dissociative symptoms with nalmefene in patients with borderline personality disorder and complex posttraumatic stress disorder]. Nervenarzt. 2022;93:503–5. https://doi.org/10.1007/s00115-021-01239-1.

Article  PubMed  Google Scholar 

Schmahl C, Kleindienst N, Limberger M, Ludäscher P, Mauchnik J, Deibler P. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol. 2012;27:61–8. https://doi.org/10.1097/YIC.0b013e32834d0e50.

Article  PubMed  Google Scholar 

Zanarini MC. Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am. 2000;23:89–101. https://doi.org/10.1016/s0193-953x(05)70145-3.

Article  CAS  PubMed  Google Scholar 

Schulze A, Cloos L, Zdravkovic M, Lis S, Krause-Utz A. On the interplay of borderline personality features, childhood trauma severity, attachment types, and social support. Borderline Personal Disord Emot Dysregul. 2022;9:35. https://doi.org/10.1186/s40479-022-00206-9.

Article  PubMed  PubMed Central  Google Scholar 

Martín-Blanco A, Ferrer M, Soler J, Arranz MJ, Vega D, Calvo N, et al. The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. Eur Arch Psychiatry Clin Neurosci. 2016;266:307–16. https://doi.org/10.1007/s00406-015-0612-2.

Article  PubMed  Google Scholar 

Fonagy P, Target M, Gergely G. Attachment and borderline personality disorder. A theory and some evidence. Psychiatr Clin North Am. 2000;23:103–22. https://doi.org/10.1016/s0193-953x(05)70146-5.

Article  CAS  PubMed  Google Scholar 

Gunderson JG, Herpertz SC, Skodol AE, Torgersen S, Zanarini MC. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029. https://doi.org/10.1038/nrdp.2018.29.

Article  PubMed  Google Scholar 

Winsper C. Borderline personality disorder: course and outcomes across the lifespan. Curr Opin Psychol. 2021;37:94–7. https://doi.org/10.1016/j.copsyc.2020.09.010.

Article  PubMed  Google Scholar 

Szyf M, Bick J. DNA methylation: a mechanism for embedding early life experiences in the genome. Child Dev. 2013;84:49–57. https://doi.org/10.1111/j.1467-8624.2012.01793.x.

Article  PubMed  Google Scholar 

Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847–54. https://doi.org/10.1038/nn1276.

Article  CAS  PubMed  Google Scholar 

Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry. 2009;65:760–9.